Literature DB >> 11828509

The chemistry and biology of ratjadone.

M Kalesse1, M Christmann, U Bhatt, M Quitschalle, E Claus, A Saeed, A Burzlaff, C Kasper, L O Haustedt, E Hofer, T Scheper, W Beil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11828509     DOI： 10.1002/1439-7633(20010903)2:9<709::AID-CBIC709>3.0.CO;2-7

Source DB:  PubMed          Journal:  Chembiochem        ISSN： 1439-4227            Impact factor:   3.164


× No keyword cloud information.
  11 in total

Review 1.  Nuclear export of proteins and drug resistance in cancer.

Authors:  Joel G Turner; Jana Dawson; Daniel M Sullivan
Journal:  Biochem Pharmacol       Date:  2011-12-20       Impact factor: 5.858

2.  An efficient, modular approach for the synthesis of (+)-strictifolione and a related natural product.

Authors:  Susanthi Jayasinghe; Phanindra K M Venukadasula; Paul R Hanson
Journal:  Org Lett       Date:  2013-12-02       Impact factor: 6.005

3.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Authors:  Joel G Turner; Douglas C Marchion; Jana L Dawson; Michael F Emmons; Lori A Hazlehurst; Peter Washausen; Daniel M Sullivan
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

4.  KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Patrizia Sanita; Flora Vitale; Francesco Marampon; Luca Ventura; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Claudio Festuccia
Journal:  BMC Cancer       Date:  2015-12-01       Impact factor: 4.430

5.  CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.

Authors:  Joel G Turner; Jana Dawson; Michael F Emmons; Christopher L Cubitt; Michael Kauffman; Sharon Shacham; Lori A Hazlehurst; Daniel M Sullivan
Journal:  J Cancer       Date:  2013-09-10       Impact factor: 4.207

Review 6.  Nucleo-cytoplasmic transport as a therapeutic target of cancer.

Authors:  Giovanni Luca Gravina; William Senapedis; Dilara McCauley; Erkan Baloglu; Sharon Shacham; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2014-12-05       Impact factor: 17.388

7.  The RanBP2/RanGAP1*SUMO1/Ubc9 SUMO E3 ligase is a disassembly machine for Crm1-dependent nuclear export complexes.

Authors:  Tobias Ritterhoff; Hrishikesh Das; Götz Hofhaus; Rasmus R Schröder; Annette Flotho; Frauke Melchior
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

Review 8.  Recent Advances in the Stereoselective Total Synthesis of Natural Pyranones Having Long Side Chains.

Authors:  Satya Kumar Avula; Biswanath Das; Rene Csuk; Ahmed Al-Rawahi; Ahmed Al-Harrasi
Journal:  Molecules       Date:  2020-04-20       Impact factor: 4.411

9.  The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates.

Authors:  Philipp Klahn; Verena Fetz; Antje Ritter; Wera Collisi; Bettina Hinkelmann; Tatjana Arnold; Werner Tegge; Katharina Rox; Stephan Hüttel; Kathrin I Mohr; Joachim Wink; Marc Stadler; Josef Wissing; Lothar Jänsch; Mark Brönstrup
Journal:  Chem Sci       Date:  2019-04-15       Impact factor: 9.825

Review 10.  Structural Basis of Targeting the Exportin CRM1 in Cancer.

Authors:  Achim Dickmanns; Thomas Monecke; Ralf Ficner
Journal:  Cells       Date:  2015-09-21       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.